[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100491192":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":34,"centralContacts":38,"locations":48,"responsibleParty":163,"collaborators":42,"id":165,"slug":42,"hasResults":166,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":42,"eligibilityCriteria":170,"healthyVolunteers":166,"sex":171,"minAge":172,"maxAge":42,"enrollmentInfo":173,"targetDuration":42,"studyType":176,"phases":177,"briefSummary":179,"conditions":180,"keywords":184,"overallStatus":51,"whyStopped":42,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":197},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Adult and pediatric patients who received an allogeneic stem cell transplant (allo-HCT)","ACTIVE_COMPARATOR","Participants are Allo-HCT recipients",[13],"Device: Photobiomodulation Therapy",{"label":15,"type":16,"description":11,"interventionNames":17},"Adult and pediatric patients who received a placebo treatment","PLACEBO_COMPARATOR",[18],"Other: Placebo sham device",[20,28],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Photobiomodulation Therapy","Participants with a history of allo-HCT and diagnosis with oral chronic GvHD randomized to the treatment arm will be treated with oral photobiomodulation\u002FPBM (via Thor LX2.3 system device) for 28 days",[9],[26,27],"PBM Therapy","Thor LX2.3 system device",{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo sham device","Participants with a history of allo-HCT and diagnosis with oral chronic GvHD randomized to the placebo arm will be treated with a placebo sham device (via Thor LX2.3 sham device setting) for 28 days",[15],[33],"Thor LX2.3 sham device setting",[35],{"name":36,"affiliation":5,"role":37},"Alina Markova, MD","PRINCIPAL_INVESTIGATOR",[39,44],{"name":36,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","6466082342",null,"markovaa@mskcc.org",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},"Doris Ponce, MD","646-608-3739","ponced@mskcc.org",[49,67,80,91,103,115,126,136,148],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"National Institute of Health (Data Collection AND Specimen Analysis)","RECRUITING","Bethesda","Maryland","20892","United States",{"type":57,"coordinates":58},"Point",[59,60],-77.10026,38.98067,{"lat":60,"lon":59},[63],{"name":64,"role":40,"phone":65,"phoneExt":42,"email":66},"Jacqueline Mays, DDS, MHSc, PhD","(301) 496-8800","jacqueline.mays@nih.gov",{"facility":68,"status":51,"city":69,"state":70,"zip":71,"country":55,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Memorial Sloan Kettering at Basking Ridge (Consent only)","Basking Ridge","New Jersey","07920",{"type":57,"coordinates":73},[74,75],-74.54932,40.70621,{"lat":75,"lon":74},[78],{"name":36,"role":40,"phone":79,"phoneExt":42,"email":42},"646-608-2342",{"facility":81,"status":51,"city":82,"state":70,"zip":83,"country":55,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Memorial Sloan Kettering Monmouth (Consent only)","Middletown","07748",{"type":57,"coordinates":85},[86,87],-74.11709,40.39428,{"lat":87,"lon":86},[90],{"name":36,"role":40,"phone":79,"phoneExt":42,"email":42},{"facility":92,"status":51,"city":93,"state":70,"zip":94,"country":55,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Memorial Sloan Kettering Cancer Center @ Bergen (Consent only)","Montvale","07645",{"type":57,"coordinates":96},[97,98],-74.02292,41.04676,{"lat":98,"lon":97},[101],{"name":102,"role":40,"phone":79,"phoneExt":42,"email":42},"Alina K Markova, MD",{"facility":104,"status":51,"city":105,"state":106,"zip":107,"country":55,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"Memorial Sloan Kettering Cancer Center @ Commack (Consent only)","Commack","New York","11725",{"type":57,"coordinates":109},[110,111],-73.29289,40.84288,{"lat":111,"lon":110},[114],{"name":102,"role":40,"phone":79,"phoneExt":42,"email":42},{"facility":116,"status":51,"city":117,"state":106,"zip":118,"country":55,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"Memorial Sloan Kettering Westchester (Consent only)","Harrison","10604",{"type":57,"coordinates":120},[121,122],-73.71263,40.96899,{"lat":122,"lon":121},[125],{"name":36,"role":40,"phone":79,"phoneExt":42,"email":42},{"facility":127,"status":51,"city":106,"state":106,"zip":128,"country":55,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Memorial Sloan Kettering Cancer Center (All Protocol Activities)","10065",{"type":57,"coordinates":130},[131,132],-74.00597,40.71427,{"lat":132,"lon":131},[135],{"name":36,"role":40,"phone":79,"phoneExt":42,"email":42},{"facility":137,"status":51,"city":138,"state":106,"zip":139,"country":55,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"Memorial Sloan Kettering Cancer Center @ Nassau (Consent only)","Uniondale","11553",{"type":57,"coordinates":141},[142,143],-73.59291,40.70038,{"lat":143,"lon":142},[146],{"name":147,"role":40,"phone":79,"phoneExt":42,"email":42},"Alina K Markova, MD, PhD",{"facility":149,"status":51,"city":150,"state":151,"zip":152,"country":55,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"University of Pittsburgh Medical Center (Data Collection Only)","Pittsburgh","Pennsylvania","15213",{"type":57,"coordinates":154},[155,156],-79.99589,40.44062,{"lat":156,"lon":155},[159],{"name":160,"role":40,"phone":161,"phoneExt":42,"email":162},"Annie Im, MD","412-864-7764","imap@upmc.edu",{"type":164,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR","100491192",false,"NCT05675930","A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant","A Multi-Center, Phase II, Randomized Double-Blind Trial to Evaluate the Efficacy and Safety of Photobiomodulation for the Treatment of Oral Chronic Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation (the LIGHT Trial)","Inclusion Criteria:\n\n* Allo-HCT recipients\n* Age ≥ 4 years-old\n* Oral cGvHD with NIH-modified OMRS score ≥ 3 who have failed ≥ 1 line of therapy, including topical corticosteroids..\n* No change in systemic immunosuppressive therapy (type or intensity level) within 2 weeks prior to enrollment.\n* If a patient is currently using another oral topical treatment for mouth lesions\u002Fsymptoms, patient must be stable on this treatment for ≥2 weeks prior to study enrollment. Patient may continue same topical dose\u002Ffrequency during the study period.\n\nExclusion Criteria:\n\n* Presence of an active uncontrolled infection. Subjects with a controlled infection receiving definitive therapy for 48 hours prior to enrollment are eligible.\n* Personal history of mucosal head and neck cancer in the past 5 years.\n* Pregnant or breastfeeding.\n* The subject or guardian is unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up, and research tests.\n* Any serious medical or psychiatric illness that could, in the Investigator's opinion, potentially interfere with the completion of treatment according to this protocol.","ALL","4 Years",{"count":174,"type":175},44,"ESTIMATED","INTERVENTIONAL",[178],"PHASE2","The purpose of this study is to find out whether photobiomodulation\u002FPBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease\u002FGVHD.",[181,182,183],"Graft-Versus-Host Disease","GVHD","Undefined",[181,182,185,186,5,187],"Chronic Graft Versus Host Disease Oral","PhotobiomoduLatIon","22-271","2026-05-20",{"date":190,"type":191},"2026-05-22","ACTUAL",{"date":193,"type":191},"2022-12-22",{"date":195,"type":175},"2026-12-22",{"name":5,"class":6},9]